基础医学与临床 ›› 2021, Vol. 41 ›› Issue (5): 744-748.

• 短篇综述 • 上一篇    下一篇

ADAM17在动脉粥样硬化发病机制中作用的研究进展

唐百壹, 文娟, 唐晓鸿*   

  1. 中南大学湘雅三医院 心血管内科, 湖南 长沙 410013
  • 收稿日期:2020-10-12 修回日期:2021-01-24 出版日期:2021-05-05 发布日期:2021-05-06
  • 通讯作者: *tangxh007007@163.com
  • 基金资助:
    湖南省自然科学基金(2020JJ4850)

Research progress on the role of ADAM17 in the pathogenesis of atherosclerosis

TANG Bai-yi, WEN Juan, TANG Xiao-hong*   

  1. Department of Cardiology, the Third Xiangya Hospital of Central South University,Changsha 410013,China
  • Received:2020-10-12 Revised:2021-01-24 Online:2021-05-05 Published:2021-05-06
  • Contact: *tangxh007007@163.com

摘要: 动脉粥样硬化是一种慢性炎性反应疾病,涉及脂质代谢失衡和免疫反应失调。去整合素-金属蛋白酶17(ADAM17)是经典的膜蛋白脱落酶,通过参与炎性反应、病理性血管生成及斑块不稳定过程,促进动脉粥样硬化的发生发展。在少数情况下,ADAM17也表现出抗动脉粥样硬化作用。因此,关注ADAM17在动脉粥样硬化中的作用机制,有利于对动脉粥样硬化诊断及其治疗提供新见解。

关键词: ADAM17, 动脉粥样硬化, 炎性反应

Abstract: Atherosclerosis is a kind of chronic inflammatory disease involving imbalance of lipid metabolism and immune disorders. The disintegrin metalloprotease 17(ADAM17) is a classic membrane protein shedding enzyme, which promotes atherosclerosis by participating in the process of inflammatory response, angiogenesis and plaque instability. In a few cases, ADAM17 also exhibits anti-atherosclerotic effects. Therefore, paying attention to the mechanism of ADAM17 in atherosclerosis will help to provide new insights into the diagnosis and treatment of atherosclerosis.

Key words: ADAM17, atherosclerosis, inflammation

中图分类号: